NZ337868A - Detection of endometrial cancer using a matrix metalloprotease - Google Patents
Detection of endometrial cancer using a matrix metalloproteaseInfo
- Publication number
- NZ337868A NZ337868A NZ337868A NZ33786898A NZ337868A NZ 337868 A NZ337868 A NZ 337868A NZ 337868 A NZ337868 A NZ 337868A NZ 33786898 A NZ33786898 A NZ 33786898A NZ 337868 A NZ337868 A NZ 337868A
- Authority
- NZ
- New Zealand
- Prior art keywords
- mmp
- uterine
- levels
- endometrial cancer
- cancer
- Prior art date
Links
- 206010014759 Endometrial neoplasm Diseases 0.000 title claims abstract description 62
- 206010014733 Endometrial cancer Diseases 0.000 title claims abstract description 60
- 238000001514 detection method Methods 0.000 title claims description 20
- 102000005741 Metalloproteases Human genes 0.000 title claims description 6
- 108010006035 Metalloproteases Proteins 0.000 title claims description 6
- 239000011159 matrix material Substances 0.000 title description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 82
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 82
- 238000000034 method Methods 0.000 claims abstract description 56
- 238000005406 washing Methods 0.000 claims abstract description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 75
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 43
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 43
- 201000011510 cancer Diseases 0.000 claims description 43
- 102000004190 Enzymes Human genes 0.000 claims description 30
- 108090000790 Enzymes Proteins 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 28
- 238000007805 zymography Methods 0.000 claims description 26
- 238000003556 assay Methods 0.000 claims description 22
- 239000012530 fluid Substances 0.000 claims description 20
- 238000002965 ELISA Methods 0.000 claims description 17
- 238000004393 prognosis Methods 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 210000005168 endometrial cell Anatomy 0.000 claims description 10
- 210000004696 endometrium Anatomy 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 230000000477 gelanolytic effect Effects 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 230000002596 correlated effect Effects 0.000 claims description 4
- 238000010562 histological examination Methods 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 230000002380 cytological effect Effects 0.000 claims description 3
- 238000000326 densiometry Methods 0.000 claims description 3
- 238000003127 radioimmunoassay Methods 0.000 claims description 3
- 238000007421 fluorometric assay Methods 0.000 claims description 2
- 238000013425 morphometry Methods 0.000 claims description 2
- 238000011160 research Methods 0.000 claims description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 abstract description 7
- 238000005259 measurement Methods 0.000 abstract description 3
- 229940088598 enzyme Drugs 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 26
- 235000011468 Albizia julibrissin Nutrition 0.000 description 25
- 241001070944 Mimosa Species 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 239000000523 sample Substances 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 21
- 208000020584 Polyploidy Diseases 0.000 description 21
- 230000036210 malignancy Effects 0.000 description 17
- 230000002357 endometrial effect Effects 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 10
- 238000001574 biopsy Methods 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 230000009545 invasion Effects 0.000 description 10
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 210000004291 uterus Anatomy 0.000 description 8
- 102000013382 Gelatinases Human genes 0.000 description 7
- 108010026132 Gelatinases Proteins 0.000 description 7
- 208000002495 Uterine Neoplasms Diseases 0.000 description 7
- 206010058314 Dysplasia Diseases 0.000 description 6
- 206010055870 Postmenopausal haemorrhage Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000002262 irrigation Effects 0.000 description 6
- 238000003973 irrigation Methods 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 206010046766 uterine cancer Diseases 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 238000004163 cytometry Methods 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000011539 total abdominal hysterectomy Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 239000000834 fixative Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 238000007804 gelatin zymography Methods 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 3
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 3
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 3
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102100030416 Stromelysin-1 Human genes 0.000 description 3
- 101710108790 Stromelysin-1 Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000009802 hysterectomy Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000002430 laser surgery Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000009595 pap smear Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010061809 Cervix carcinoma stage 0 Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102100030417 Matrilysin Human genes 0.000 description 2
- 108090000855 Matrilysin Proteins 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 208000016018 endometrial polyp Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002632 myometrial effect Effects 0.000 description 2
- 210000000754 myometrium Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 206010046811 uterine polyp Diseases 0.000 description 2
- 230000009790 vascular invasion Effects 0.000 description 2
- GUEHESDOJBMSSE-UHFFFAOYSA-M (2-aminophenyl)mercury(1+);acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1N GUEHESDOJBMSSE-UHFFFAOYSA-M 0.000 description 1
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- -1 5mmol/L CaClj Chemical compound 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 238000009649 Feulgen staining Methods 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010058823 Ovarian mass Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 108010071626 caseinase Proteins 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003370 dye binding method Methods 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
- 208000029382 endometrium adenocarcinoma Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- UQNZJQUFLKWHHH-YBFXNURJSA-N n-[(e)-1-(2-oxochromen-3-yl)ethylideneamino]pyridine-4-carboxamide Chemical compound C=1C2=CC=CC=C2OC(=O)C=1C(/C)=N/NC(=O)C1=CC=NC=C1 UQNZJQUFLKWHHH-YBFXNURJSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 206010034260 pelvic mass Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000022159 squamous carcinoma in situ Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPO5736A AUPO573697A0 (en) | 1997-03-20 | 1997-03-20 | Diagnosis of endometrial cancer |
| PCT/AU1998/000189 WO1998042865A1 (en) | 1997-03-20 | 1998-03-20 | Detection of endometrial cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ337868A true NZ337868A (en) | 2002-05-31 |
Family
ID=3800039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ337868A NZ337868A (en) | 1997-03-20 | 1998-03-20 | Detection of endometrial cancer using a matrix metalloprotease |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6607894B1 (enExample) |
| EP (1) | EP0979304B1 (enExample) |
| JP (2) | JP4183757B2 (enExample) |
| KR (1) | KR20010006344A (enExample) |
| CN (1) | CN1257550A (enExample) |
| AT (1) | ATE331039T1 (enExample) |
| AU (1) | AUPO573697A0 (enExample) |
| CA (1) | CA2284099C (enExample) |
| DE (1) | DE69835010T2 (enExample) |
| ES (1) | ES2268767T3 (enExample) |
| MY (1) | MY119567A (enExample) |
| NZ (1) | NZ337868A (enExample) |
| WO (1) | WO1998042865A1 (enExample) |
| ZA (1) | ZA982403B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6228596B1 (en) * | 1998-03-05 | 2001-05-08 | Diadexus, Inc. | Method of detecting and monitoring endometrial and uterine cancers |
| AUPQ219799A0 (en) | 1999-08-13 | 1999-09-02 | R. Lurie Pty Ltd | Apparatus for obtaining potological samples |
| US7071164B2 (en) | 2001-08-16 | 2006-07-04 | Kimberly-Clark Worldwide, Inc. | Anti-cancer and wound healing compounds |
| US7186693B2 (en) | 2001-08-16 | 2007-03-06 | Kimberly - Clark Worldwide, Inc. | Metalloproteinase inhibitors for wound healing |
| US7094754B2 (en) | 2001-08-16 | 2006-08-22 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
| US6906036B2 (en) | 2001-08-16 | 2005-06-14 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
| DE10217677A1 (de) | 2002-04-19 | 2003-11-06 | Bayer Ag | Verwendung von Aufhellern zur Herstellung von Streichmassen |
| US7148194B2 (en) | 2002-12-30 | 2006-12-12 | Kimberly-Clark Worldwide, Inc. | Method to increase fibronectin |
| US7189700B2 (en) | 2003-06-20 | 2007-03-13 | Kimberly-Clark Worldwide, Inc. | Anti-chrondrosarcoma compounds |
| US20060003391A1 (en) * | 2003-08-11 | 2006-01-05 | Ring Brian Z | Reagents and methods for use in cancer diagnosis, classification and therapy |
| US20050112622A1 (en) * | 2003-08-11 | 2005-05-26 | Ring Brian Z. | Reagents and methods for use in cancer diagnosis, classification and therapy |
| ATE463743T1 (de) * | 2004-07-23 | 2010-04-15 | Ct De Rech Public De La Sante | Überwachung von herzversagen |
| US20080131916A1 (en) * | 2004-08-10 | 2008-06-05 | Ring Brian Z | Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy |
| RU2007133660A (ru) * | 2005-02-09 | 2009-03-20 | Дженентек, Инк. (Us) | Ингибирование шеддинга her2 антагонистами матриксной металлопротеиназы |
| US7504225B2 (en) * | 2005-05-12 | 2009-03-17 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
| RU2304782C1 (ru) * | 2005-12-28 | 2007-08-20 | Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова | Способ прогнозирования рецидива эндометриоидной кисты яичника |
| US8592393B2 (en) | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| WO2009059284A2 (en) | 2007-11-02 | 2009-05-07 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
| ES2458818T3 (es) * | 2009-04-16 | 2014-05-07 | Momenta Pharmaceuticals, Inc. | Métodos para evaluar la actividad de una composición de polisacárido |
| EP2848700B1 (en) * | 2009-07-24 | 2017-10-04 | Geadic Biotec, AIE. | Markers for endometrial cancer |
| CN102985443B (zh) | 2010-04-16 | 2017-05-10 | 动量制药公司 | 组织靶向 |
| RU2430371C1 (ru) * | 2010-04-26 | 2011-09-27 | Учреждение Российской академии наук Институт ядерной физики им. Г.И. Будкера Сибирского отделения РАН (ИЯФ СО РАН) | Способ дифференциальной диагностики и прогноза миомы и рака эндометрия |
| US10017585B2 (en) | 2010-06-17 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Methods and compositions for promoting hair growth |
| WO2012167163A2 (en) * | 2011-06-03 | 2012-12-06 | University Of South Alabama | Methods and compositions for detecting endometrial or ovarian cancer |
| AU2012312071C1 (en) * | 2011-09-22 | 2017-08-24 | Memorial Sloan-Kettering Cancer Center | Detecting ovarian cancer |
| SI2809801T1 (sl) * | 2012-01-31 | 2018-12-31 | SPEISER, Paul | Neinvazivna diagnostika raka |
| EP3003324A4 (en) | 2013-05-28 | 2017-01-25 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
| US10564162B2 (en) * | 2014-07-02 | 2020-02-18 | Bionomics Limited | Predictive biomarkers |
| MX381948B (es) * | 2015-02-06 | 2025-03-13 | Quest Diagnostics Invest Llc | Composiciones y metodos para determinar el pronostico de cancer de endometrio. |
| BR112018072498A2 (pt) * | 2016-05-04 | 2019-03-12 | Fundacio Hospital Univ Vall Dhebron Institut De Recerca | marcadores de câncer do endométrio |
| IN202021002695A (enExample) | 2020-01-21 | 2021-07-23 | ||
| CN112961921B (zh) * | 2021-03-26 | 2022-07-01 | 中国医学科学院北京协和医院 | 一种用于判断早期子宫内膜癌预后的制剂及复发风险模型 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5280106A (en) * | 1988-05-20 | 1994-01-18 | Liotta Lance A | Matrix metalloproteinase peptides: role in diagnosis and therapy |
| US5324634A (en) * | 1992-03-31 | 1994-06-28 | The Research Foundation Of State University Of New York | Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer |
| WO1994005807A1 (en) * | 1992-08-28 | 1994-03-17 | Dickson Robert B | Matrix-degrading metalloproteinase |
| EP0674710B1 (en) * | 1992-11-16 | 2003-05-02 | Cancer Research Fund Of Contra Costa | Peptides with broad neoplastic specificity |
-
1997
- 1997-03-20 AU AUPO5736A patent/AUPO573697A0/en not_active Abandoned
-
1998
- 1998-03-20 MY MYPI98001218A patent/MY119567A/en unknown
- 1998-03-20 CN CN98805312A patent/CN1257550A/zh active Pending
- 1998-03-20 NZ NZ337868A patent/NZ337868A/en not_active IP Right Cessation
- 1998-03-20 AT AT98909221T patent/ATE331039T1/de not_active IP Right Cessation
- 1998-03-20 ES ES98909221T patent/ES2268767T3/es not_active Expired - Lifetime
- 1998-03-20 ZA ZA982403A patent/ZA982403B/xx unknown
- 1998-03-20 JP JP54453698A patent/JP4183757B2/ja not_active Expired - Fee Related
- 1998-03-20 CA CA2284099A patent/CA2284099C/en not_active Expired - Fee Related
- 1998-03-20 WO PCT/AU1998/000189 patent/WO1998042865A1/en not_active Ceased
- 1998-03-20 KR KR1019997009429A patent/KR20010006344A/ko not_active Withdrawn
- 1998-03-20 DE DE69835010T patent/DE69835010T2/de not_active Expired - Lifetime
- 1998-03-20 US US09/381,454 patent/US6607894B1/en not_active Expired - Fee Related
- 1998-03-20 EP EP98909221A patent/EP0979304B1/en not_active Expired - Lifetime
-
2007
- 2007-01-09 JP JP2007001867A patent/JP2007202556A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AUPO573697A0 (en) | 1997-04-10 |
| ATE331039T1 (de) | 2006-07-15 |
| CN1257550A (zh) | 2000-06-21 |
| US6607894B1 (en) | 2003-08-19 |
| DE69835010T2 (de) | 2007-06-06 |
| MY119567A (en) | 2005-06-30 |
| EP0979304A1 (en) | 2000-02-16 |
| DE69835010D1 (de) | 2006-08-03 |
| JP2007202556A (ja) | 2007-08-16 |
| WO1998042865A1 (en) | 1998-10-01 |
| ZA982403B (en) | 1998-10-21 |
| CA2284099A1 (en) | 1998-10-01 |
| CA2284099C (en) | 2010-04-27 |
| EP0979304A4 (en) | 2003-06-11 |
| KR20010006344A (ko) | 2001-01-26 |
| ES2268767T3 (es) | 2007-03-16 |
| EP0979304B1 (en) | 2006-06-21 |
| JP2002501613A (ja) | 2002-01-15 |
| JP4183757B2 (ja) | 2008-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6607894B1 (en) | Matrix metalloproteinase levels as indicators of endometrial cancer | |
| Bianco Jr et al. | Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. | |
| CN112601961B (zh) | 通过尿液生物标志物的方式体外诊断前列腺癌的方法 | |
| JP5155309B2 (ja) | 患者の循環液中のＭＭＰ−７の測定を利用した転移した膀胱ガンを診断およびモニターするためのｉｎｖｉｔｒｏ方法 | |
| Lopata et al. | Detection of endometrial cancer by determination of matrix metalloproteinases in the uterine cavity | |
| US6221623B1 (en) | Biochemical methods for detecting cervical dysplasia and cancer | |
| Harada et al. | Expression of matrix metalloproteinase in the fluids of renal cystic lesions | |
| Yang et al. | A Significant Elevation of Plasma Level of Matrix Metalloproteinase—9 in Patients With High-Grade Intraepithelial Neoplasia and Early Squamous Cell Carcinoma of the Uterine Cervix | |
| WO1995004281A1 (en) | Quantitative method of measuring cancer cell urokinase and metastatic potential | |
| AU728286B2 (en) | Detection of endometrial cancer | |
| Nordström et al. | Laminin-5 g 2 chain as an invasivity marker for uni-and multifocal lesions in the lower anogenital tract | |
| US20070269831A1 (en) | Method for Early Detection of Ovarian Cancer | |
| MXPA99008616A (en) | Detection of endometrial cancer | |
| Bollmann et al. | Quantitative molecular grading of bladder tumours: a tool for objective assessment of the biological potential of urothelial neoplasias | |
| Bazzett et al. | Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies | |
| US20080213815A1 (en) | Diagnosing breast cancer by seprase level | |
| WO2000023613A1 (en) | A method of assessing a matter associated with parturition in a pregnant individual | |
| Vries et al. | 1826: Development of Prostate Specific Antigen Over Time in Males with Screen Detected Adenocarcinoma of the Prostate Following a Watchful Waiting Policy | |
| Degnim et al. | Refining risk assessment in women with atypical hyperplasia | |
| Kapucuoglu et al. | Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma | |
| Datta | PSA in Prostate Cancer Diagnosis | |
| Purified | Improving the Clinical Utility of the Serum PSA Test | |
| Talvensaari-Mattila | MMP-2 immunoreactive protein in breast carcinoma and neoplastic cervical lesions: mMP-2 is a new prognostic factor in breast carcinoma | |
| Sarkar et al. | Role of Morphometry and Proliferative Activity Markers in Assessment of Endometrial Glandular Lesions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AVOD | Application void | ||
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| ASS | Change of ownership |
Owner name: DIAGNOTECH PTY LTD, AU Free format text: OLD OWNER(S): DIAGNOTECH PTY LTD; PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH; THE UNIVERSITY OF MELBOURNE |
|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |